Conditions: Non-Squamous Non-Small Cell Lung Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 264
Healthy volunteers: no

Brief summary:
This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy. The anticipated time on study treatment is until disease progression, unacceptable toxicity or death.

Detailed description:

Arms:
arm 1: Participants will receive erlotinib orally daily until disease progression, unacceptable toxicity or death.

Interventions: intervention 1: Erlotinib
Intervention descriptions: intervention 1: Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.

Protocol document: